2023年2月17日,美国FDA加速批准sparsentan上市许可申请,使其成为唯一获批的治疗免疫球蛋白A型肾病(immunoglobulin A kidney disease,IgAN)的非免疫抑制药物,该药适用于具有疾病快速进展风险,且尿蛋白与肌酐比值(urine protein/creatin...2023年2月17日,美国FDA加速批准sparsentan上市许可申请,使其成为唯一获批的治疗免疫球蛋白A型肾病(immunoglobulin A kidney disease,IgAN)的非免疫抑制药物,该药适用于具有疾病快速进展风险,且尿蛋白与肌酐比值(urine protein/creatinine ratio,UPCR)≥1.5 g·g^(-1)的原发性IgAN成人患者。sparsentan是一种新型的非免疫抑制、单分子、双效内皮素-血管紧张素受体拮抗剂,可双重阻断内皮素A型(endothelin type A,ETA)和血管紧张素Ⅱ型1受体(angiotensinⅡtype 1 receptor,AT1),发挥保护肾小球足细胞和减少蛋白尿的作用。虽然美国FDA药品标签中包含了2个针对sparsentan的黑框警告,但临床试验表明sparsentan耐受性和安全性较好,相较于厄贝沙坦治疗,其提供了更为显著的临床益处,使患者蛋白尿显著减少,有助于延缓肾脏功能的减退。展开更多
Chitosan is a nontoxic natural polysaccharide with good biocompatibility.It can form polymer\|metal complexes with many metal cations for its extra electron pair of nitrogen.The complexes exhibit high sorptive capacit...Chitosan is a nontoxic natural polysaccharide with good biocompatibility.It can form polymer\|metal complexes with many metal cations for its extra electron pair of nitrogen.The complexes exhibit high sorptive capacity and good selectivity for urea.The sorption capacity was influenced by the metal content in the complex,time of sorption,concentration of urea etc.The sorption capacities were 83.6,79.1,72.9,69.4 and 53.4 mg/g for urea by the chitosan metal complexes of Cu(Ⅱ),Cd(Ⅱ),Co(Ⅱ),Zn(Ⅱ) and Fe(Ⅲ),respectively at pH 6.0 and the concentration of urea being 1 300 mg/L.展开更多
文摘Chitosan is a nontoxic natural polysaccharide with good biocompatibility.It can form polymer\|metal complexes with many metal cations for its extra electron pair of nitrogen.The complexes exhibit high sorptive capacity and good selectivity for urea.The sorption capacity was influenced by the metal content in the complex,time of sorption,concentration of urea etc.The sorption capacities were 83.6,79.1,72.9,69.4 and 53.4 mg/g for urea by the chitosan metal complexes of Cu(Ⅱ),Cd(Ⅱ),Co(Ⅱ),Zn(Ⅱ) and Fe(Ⅲ),respectively at pH 6.0 and the concentration of urea being 1 300 mg/L.
